Sabine Ott News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Sabine ott. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Sabine Ott Today - Breaking & Trending Today
Sanofi partners with SIRION to improve AAV capsids for gene therapy treatments 24th February 2021 SIRION Biotech has signed a license and collaboration with Sanofi to develop improved adeno-associated virus capsids for gene therapy treatments for disorders affecting major human organs. Sanofi, working with SIRION Biotech and professor Dirk Grimm, a scientist in the field of AAV biology and application working at Heidelberg University Hospital in Germany, will combine their technology platforms to create next-generation AAV vectors. As part of the collaboration, the partners will aim to develop new and modified AAV capsids with a safe product profile and improved specificity, with higher gene delivery efficiency. ....
Posted on 192 SIRION Biotech GmbH, a world leader in viral vector-based gene delivery technologies for gene & cell therapy, announced today that it signed a license and collaboration agreement with Sanofi, a global biopharmaceutical company, to develop improved tissue-selective adeno-associated virus (AAV) vectors to realize effective gene therapy treatments for disorders affecting major human organs. AAV vectors are a promising and clinically validated gene delivery platform for the potential treatment of a variety of human diseases. Sanofi, together with SIRION Biotech and Prof. Dirk Grimm, a world-renowned and pioneering scientist in the field of AAV biology and application working at Heidelberg University Hospital (Germany), will combine their proprietary technology platforms to create a next generation of AAV vectors. The goal of this collaboration is to develop new and modified AAV capsids that exhibit ....
(2) Joining forces to develop gene therapies for multiple life-threatening disorders SIRION Biotech GmbH, a world leader in viral vector-based gene delivery technologies for gene cell therapy, announced today that it signed a license and collaboration agreement with Sanofi, a global biopharmaceutical company, to develop improved tissue-selective adeno-associated virus (AAV) vectors to realize effective gene therapy treatments for disorders affecting major human organs. AAV vectors are a promising and clinically validated gene delivery platform for the potential treatment of a variety of human diseases. Sanofi, together with SIRION Biotech and Prof. Dirk Grimm, a world-renowned and pioneering scientist in the field of AAV biology and application working at Heidelberg University Hospital (Germany), will combine their proprietary technology platforms to create a next generation of AAV vectors. The goal of this collaboration is to develop new and modified AAV capsids ....